• Home
  • Media
  • Press Releases
  • A Strategic Partnership to Establish the First Glargine Manufacturing Facility in the MENA Region in the UAE

A Strategic Partnership to Establish the First Glargine Manufacturing Facility in the MENA Region in the UAE

2022-10-21
UAE announces industrial deals worth AED 260m to manufacture medical equipment locally
  • Abu Dhabi Medical Devices Company, PureHealth, Borouge, Julphar among companies signing MoU that will boost exports and increase UAE’s global competitiveness
  • Partnerships include new factories and production lines in Abu Dhabi and Ras Al Khaimah to supply medicines and medical equipment to local, regional, and global markets
  • MoUs follow Make it in the Emirates Forum that convened national companies in May to explore local manufacturing partnerships
  
 
Abu Dhabi, UAE: 21 October 2022 – The Ministry of Industry and Advanced
Technology (MoIAT) today announced the signing of a pair of memoranda of
understanding (MoU) together worth AED 260 million ($70.8 million) between major
pharmaceutical and medical devices companies in the UAE.
Signed in the presence of Her Excellency Sarah bint Youssef Al Amiri, Minister of State
for Public Education and Advanced Technology, the partnerships are in line with the
National Strategy for Industry and Advanced Technology and the ICV Program, which
aim to attract investors and manufacturers to the UAE’s pharmaceutical and medical
equipment sectors, among others.
Under the partnerships, PureHealth, one of the largest healthcare providers in the UAE
and a member of the ministry's National ICV Program, will work with Abu Dhabi Medical
Devices Company (ADMD), which is a subsidiary of Abu Dhabi National Industrial
Projects, as well as Abu Dhabi Ports Group and Abu Dhabi Polymers Company
(Borouge) to establish a AED 110 million medical supplies production line in Abu Dhabi.
Under the MoU, Borouge will provide raw materials while Abu Dhabi Ports Group will
provide industrial land in ICAD 1 for the production of medical syringes, administration
devices, and blood collection tubes.
Under a separate MoU, PureHealth and Gulf Pharmaceutical Industries Company
(Julphar) will establish the first factory in the Middle East to produce Glargine (the first
long-acting biological alternative to insulin) for the treatment of diabetes. The AED 150
million manufacturing facilities will be built in Ras Al Khaimah and will enable the UAE to
obtain an insulin substitute at more competitive prices. It will also support exports to
regional and global markets where there is an increasing demand for insulin substitutes.
Signatories
 
The MoU between PureHealth and Abu Dhabi Medical Devices Company was signed
by: Farhan Malik, CEO of PureHealth Group; Mounir Haddad, CEO of Abu Dhabi
Medical Devices Company; Abdullah Humaid Al Hamelli, Head of Industrial Cities and
Freezones, Abu Dhabi Ports, and Hazeem Sultan Al Suwaidi, CEO, Borouge.
The second MoU, between PureHealth and Julphar was attended by Sheikh Saqr bin
Humaid Al Qasimi, Chairman of the Board of Directors of Gulf Pharmaceutical Industries
– Julphar. It was signed by Mr. Malik and Dr. Essam Mohamed, CEO of Julphar.
Both signings were attended by: His Excellency Omar Al Suwaidi, Undersecretary of the
Ministry of Industry and Advanced Technology; His Excellency Dr Amin Al Amiri,
Assistant Undersecretary for the Health Regulation Sector at the Ministry of Health and
Community Protection; Sameh Al Qubaisi, Director General - Economic Affairs at Abu
Dhabi Department of Economic Development; His Excellency Abdullah Al Shamsi,
Assistant Undersecretary for the Industrial Development Sector at the Ministry of
Industry and Advanced Technology; and Omar Najm, Director of the Executive Affairs
Office at the Department of Health.
Make it in the Emirates
The MoUs follow the Make in the Emirates Forum, which was hosted by the Ministry of
Industry and Advanced Technology in May. The forum highlighted industrial investment
opportunities and identified products that can be manufactured locally, including in the
pharmaceutical and medical supplies sector.
This kind of cooperation between major national companies is a draw for international
investors and manufacturers working in priority sectors. The Make it in the Emirates
campaign goes hand-in-hand with the National In-Country Value (ICV) Program, in
which national companies help to redirect government procurement spending into the
local economy.
Empowering priority sectors
His Excellency Dr Sultan bin Ahmed Al Jaber, Minister of Industry and Advanced
Technology commented: “These partnerships are in line with the directives of our
leadership which aim to empower and stimulate sectors, enhance investment, and
support the UAE’s position as a global industrial hub. The partnerships are in line with
our strategic objectives and reflect the important role of the ministry's Make it in the
Emirates Forum, which identified more than 300 products that can be produced locally in
priority sectors such as pharmaceuticals and medical equipment."
His Excellency said: “These partnerships will play a significant role in boosting economic
development through the National ICV Program. The ICV Program is one of the
ministry's Projects of the 50 supporting economic growth. It increases supply chain
resilience and encourages companies to manufacture quality products in the UAE that
can be exported globally.”
Invitation to investors
 
His Excellency Dr Al Jaber called on investors and industrialists from around the world to
seize the investment opportunities offered by the UAE’s industrial growth. He urged
companies to take advantage of the Make it in the Emirates campaign and the UAE's
industrial investment environment. This environment includes competitive financing
opportunities, business incubators, feasibility studies, a strategic location, a world-class
logistics infrastructure, the UAE’s global credibility, legislation that protects investor
rights, and easy access to global markets.
For her part, Her Excellency Al Amiri said: “MoIAT is working under the directives of the
UAE leadership to stimulate growth in priority sectors, such as medical technology and
devices. The expansion of production capacity resulting from these partnerships
contributes to achieving self-sufficiency and increasing global exports.”
Her Excellency added: “These agreements will strengthen local supply chains and help
enhance self-sufficiency in medicines and healthcare products. The memoranda of
understanding also reflect efforts by major national companies and institutions to
integrate and collaborate while enhancing opportunities for citizens to obtain quality
jobs.”
Sheikh Saqr Bin Humaid Al Qasimi, Chairman of the board of Directors of Julphar, said:
“Julphar is focused on developing its capacity to provide high-quality healthcare
solutions to the Middle East and Africa. Over more than four decades, we have
established our name as an Emirati brand with a successful model for pioneering the
manufacture of medicines. Julphar leverages the technical and scientific capabilities that
position the UAE as a leader in the pharmaceutical sector. This new partnership
contributes to increasing production capabilities and exports in line with our strategy to
reach new markets while continuing to launch new products to compete in the global
market.”
Abdullah Al Hameli, CEO, Economic Cities & Free Zones, AD Ports Group, said: “AD
Ports Group collaborates with leading UAE organisations from the public and private
sectors to achieve the objectives of the National Strategy for Industry and Advanced
Technology, and position the UAE as an advanced hub for strategic industries.
“These important agreements are aligned with AD Ports Group’s commitment to drive
economic diversification in line with the vision of our wise leadership. Khalifa Economic
Zones Abu Dhabi - KEZAD Group has a proven record of success in supporting the
pharmaceutical industry through advanced infrastructure and services provided by its
Life Sciences Hub. This enables us to sustain more growth, attract additional
manufacturers and increase pharmaceutical investments regionally and globally.
“We are confident that this strategic cooperation between leading UAE organisations will
play a key role in enhancing and supporting the pharmaceutical and medical supply
 
chains. KEZAD Group will continue to provide exceptional capabilities to ensure the
success of this project and offer competitive advantages and facilities to its partners.”
Hazeem Sultan Al Suwaidi, CEO of Borouge, said: “We are pleased to enter this
important strategic industrial partnership with the support of the Ministry of Industry and
Advanced Technology. We will provide partners with our locally made polyolefins that
are tailored for the healthcare sector and to enhance people’s lives. This collaboration
comes as part of Borouge’s ongoing efforts to support the Make it in the Emirates
campaign, strengthening our position as a leading provider of high-quality polyolefin
solutions in the region.”
Dr. Essam Mohamed, CEO of Gulf Pharmaceutical Industries Manufacturers (Julphar),
said: “This MoU supports Julphar's production of Glargine and other medicines for the
local and global market. As for covering the needs of the MENA region and other
international countries, an agreement will be made at a later date. With 12 factories in
Ras Al Khaimah, worth AED 150 million, and an annual production capacity that meets
the needs of the local and global market, Julphar will reinforce is position as a leading
manufacturer of Glargine globally. This agreement represents a qualitative leap for the
UAE, for Julphar, and for the pharmaceutical industry, in line with the Make It in the
Emirates initiative.”
In his comments, Farhan Malik, Group CEO of PureHealth, said: “At PureHealth, we are
thankful to the Ministry of Industry and Advanced Technology for facilitating and giving
the platform to companies, to create synergies which support the national industrial
agenda of UAE. The ‘Make it in the Emirates’ is a key initiative that brought different
sectors, including healthcare entities, on a common platform. Today’s MoUs are
actionable results from the follow-up to the ‘Make it in the Emirates’ Forum. At the
Forum, we at PureHealth, along with all the industry colleagues, made a commitment to
MOIAT to boost the In-Country Value. We are committed and are proud to be part of the
ICV program, which is an important long-term program aimed at building a sustainable
and prosperous future for UAE. We believe the ICV is not a nice-to-have but a must-
have program and we urge all entities – especially in the healthcare sector to adopt ICV
program.
Malik added: “ICV is critical in the healthcare sector because the sector needs to be
resilient to be less dependent on external factors. We are already in the midst of the
Fourth Industrial Revolution, which is a fusion of the biological, physical, and digital
worlds. Medtech, biotech, and biopharma are at the core of the Fourth Industrial
Revolution. As we all focus on embracing Industry 4.0, supporting the local pharma,
biotech and medtech sectors is key to maximizing the benefits of this industrial
revolution. With a commitment to the ICV program, we look forward to celebrating many
of these collaborations together with other entities to play our role in supporting the
growth and prosperity of the UAE’s economy.”
Mr. Mounir Haddad , CEO of Abu Dhabi Medical Devices Company (ADMD) said: “I
would like to thank the Ministry of Industry & Advanced Technology for this initiative to
 
support the local manufacturing industry. This partnership with PureHealth, Abu Dhabi
Ports, and (Borouge) will allow us to expand our manufacturing area, increase our
manufacturing capacity, and add new products to our portfolio to supply the local health
sector with high quality products.”
He added: “We are grateful to be based in Abu Dhabi where we have the full support
from the government in addition to the importance of our geographical location that
allows us to easily access global markets in terms of ease of shipments and high
reputation of Emirati products.”
Industrial growth
The industrial partnership between Pure Health, Julphar, Abu Dhabi Medical Devices
and other government and private entities represents an exemplary model in industrial
integration and cooperation. Through these kinds of partnerships, companies will be able
to procure products locally, supporting supply chain localization and local suppliers. The
ministry hopes they will pave the way for similar partnerships across sectors.
 
 
This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, refer to our Cookie Policy.